Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
In Vivo. 2021 Nov-Dec;35(6):3423-3430. doi: 10.21873/invivo.12642.
BACKGROUND/AIM: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy.
This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020.
A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS.
Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.
背景/目的：对于接受铂类细胞毒性化疗后接受免疫治疗的非小细胞肺癌（NSCLC）患者，格拉斯哥预后评分（GPS）的预后作用知之甚少。
本研究使用了韩国天主教医疗中心 2018 年 1 月至 2020 年 9 月的肺癌队列。
共纳入 78 例接受免疫治疗作为二线或进一步治疗的 NSCLC 患者。较高的 GPS 值是免疫相关无进展生存期（irPFS）和总生存期（OS）较短的显著预测因素。程序性死亡配体 1（PD-L1）表达≥50%的 HR 为 0.249，GPS 为 2 的 HR 为 9.73。年龄较大、PD-L1 表达较低和较高的 GPS 值与较短的 OS 独立相关。
较高的 GPS 值被确定为接受二线或进一步免疫治疗的 NSCLC 患者 OS 和 irPFS 的不良预后因素。
